文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-PSFA-01的設計、臨床前評估及首次人體PET研究:一種PSMA/FAP異雙價示蹤劑

Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-11-09

針對前列腺癌腫瘤異質性導致PSMA表達不足的問題,研究者開發了靶向PSMA和FAP的異雙價示蹤劑[68Ga]Ga-PSFA-01,在體外和荷瘤小鼠中評估雙受體親和力與顯像表現,並在一例轉移性前列腺癌患者中進行首次人體PET/CT,與[68Ga]Ga-FAPI-04和[68Ga]Ga-PSMA-11比較病灶檢出。

要点

  • PSFA-01與[68Ga]Ga-PSFA-01對FAP和PSMA均有高親和力,Ki為0.14-1.02 nM。
  • 小鼠micro-PET/CT中22Rv1腫瘤對[68Ga]Ga-PSFA-01的攝取SUVmax為3.89±0.47,高於[68Ga]Ga-PSMA-11的2.96±0.48。
  • 臨床病例中[68Ga]Ga-PSFA-01檢出21個病灶,多於[68Ga]Ga-FAPI-04的3個和[68Ga]Ga-PSMA-11的13個。

核心结论

  • [68Ga]Ga-PSFA-01在體外和體內均顯示滿意的PSMA和FAP雙受體靶向性能。
  • 本研究凸顯[68Ga]Ga-PSFA-01 PET/CT檢測前列腺癌轉移瘤的臨床可行性,較單靶點[68Ga]Ga-PSMA-11和[68Ga]Ga-FAPI-04更靈敏。
  • 作者認為PSMA/FAP雙靶向放射性核素治療可能有望克服前列腺癌腫瘤異質性和PSMA表達不足的挑戰。

研究设计与样本

  • 臨床前研究:合成前體PSFA-01,體外評估雙受體結合親和力與細胞攝取,並在22Rv1和U87MG荷瘤小鼠中進行micro-PET/CT顯像。
  • 首次人體研究:在一例轉移性前列腺癌患者中評估[68Ga]Ga-PSFA-01 PET/CT的臨床可行性,並與[68Ga]Ga-FAPI-04和[68Ga]Ga-PSMA-11 PET/CT結果比較。
  • 臨床試驗註冊號NCT06387381,註冊日期2024年5月1日。

主要发现

  • PSFA-01和[natGa]Ga-PSFA-01對FAP和PSMA蛋白均顯示高親和力,Ki為0.14-1.02 nM。
  • micro-PET/CT中22Rv1腫瘤對[68Ga]Ga-PSFA-01的攝取SUVmax為3.89±0.47,高於[68Ga]Ga-PSMA-11的SUVmax 2.96±0.48。
  • U87MG腫瘤對[68Ga]Ga-PSFA-01的攝取SUVmax為7.29±1.13,顯著高於[68Ga]Ga-FAPI-04的SUVmax 0.28±0.12,注射後1小時腫瘤/肌肉比值為12.68±1.93。
  • 臨床病例中[68Ga]Ga-PSFA-01清晰識別原發腫瘤和轉移病灶共21個,在病灶數和特異性方面優於[68Ga]Ga-FAPI-04(3個病灶)和[68Ga]Ga-PSMA-11(13個病灶)。

关键数值与推荐

  • PSFA-01和[natGa]Ga-PSFA-01對FAP和PSMA的Ki為0.14-1.02 nM。
  • 22Rv1腫瘤[68Ga]Ga-PSFA-01 SUVmax 3.89±0.47 vs [68Ga]Ga-PSMA-11 SUVmax 2.96±0.48。
  • U87MG腫瘤[68Ga]Ga-PSFA-01 SUVmax 7.29±1.13 vs [68Ga]Ga-FAPI-04 SUVmax 0.28±0.12,注射後1小時腫瘤/肌肉比值12.68±1.93。
  • 臨床病例病灶檢出數:[68Ga]Ga-PSFA-01為21個,[68Ga]Ga-FAPI-04為3個,[68Ga]Ga-PSMA-11為13個。

临床怎么用

  • 原文未據此給出臨床推薦。

局限性

  • 原文未報告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate cancer (PCa), characterized by tumor heterogeneity, may exhibit low or absent prostate-specific membrane antigen (PSMA) expression in cancerous lesions, limiting the detection sensitivity of monospecific probes. Given that fibroblast activation protein (FAP) is frequently overexpressed in the tumor microenvironment (TME), we developed a PSMA/FAP dual-targeting tracer to address this limitation. METHODS: The precursor (PSFA-01) was synthesized by coupling a quinolone-based FAP-targeting scaffold and EuK with HBED-CC via amide bonds. The dual-receptor-binding affinity and cell uptake of PSFA-01 and [natGa]Ga-PSFA-01 was evaluated in vitro. Micro-PET/CT imaging was performed on 22Rv1 and U87MG tumor-bearing mice. The feasibility of [68Ga]Ga-PSFA-01 PET/CT in a clinical setting was evaluated in a metastatic prostate cancer patient, and the results were compared with those of [68Ga]Ga-FAPI-04 and [68Ga]Ga-PSMA-11 PET/CT. RESULTS: PSFA-01 and [natGa]Ga-PSFA-01 showed high affinity for both FAP and PSMA proteins (Ki = 0.14-1.02 nM). On micro-PET/CT imaging, the 22Rv1 tumor uptake of [68Ga]Ga-PSFA-01 (SUVmax = 3.89 ± 0.47) was higher than that of [68Ga]Ga-PSMA-11 (SUVmax = 2.96 ± 0.48). The U87MG tumor uptake of [68Ga]Ga-PSFA-01 was significantly higher (SUVmax = 7.29 ± 1.13) than [68Ga]Ga-FAPI-04 (SUVmax = 0.28 ± 0.12), showing tumor to muscle ratio as 12.68 ± 1.93 at 1 h p.i. On clinical trial, the primary tumor and metastatic lesions were distinctly identified by [68Ga]Ga-PSFA-01 (21 lesions), demonstrating superior performance compared to [68Ga]Ga-FAPI-04 (3 lesions) and [68Ga]Ga-PSMA-11 (13 lesions) in terms of lesion count and specificity. CONCLUSIONS: [68Ga]Ga-PSFA-01 exhibited satisfactory PSMA and FAP dual-receptor-targeting properties both in vitro and in vivo. This study highlights the clinical feasibility of [68Ga]Ga-PSFA-01 PET/CT for detecting metastatic tumors of prostate cancer more sensitively compared to monomeric [68Ga]Ga-PSMA-11 and [68Ga]Ga-FAPI-04, which also suggests that a PSMA/FAP dual-targeted radionuclide therapy could potentially overcome challenges related to tumor heterogeneity and insufficient PSMA expression in PCa. TRIAL REGISTRATION: Clinical trial registry NCT06387381, Registered 1 May 2024.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhang X, Zhang X, et al. Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39520516. doi:10.1007/s00259-024-06965-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。